Lataa...
Therapy for lower-risk MDS
Lower-risk myelodysplastic syndromes (MDS) are characterized by the presence of dysplasia, low bone marrow blast percentage, low number and depth of cytopenia(s), and relatively good-risk karyotpic and molecular abnormalities. A score of ≤3.5 on the Revised International Prognostic Scoring System cl...
Tallennettuna:
| Julkaisussa: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727572/ https://ncbi.nlm.nih.gov/pubmed/33275714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000127 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|